In vivo molecular imaging is a powerful tool to analyze the human body. Precision medicine is receiving high attention these days, and molecular imaging plays an important role as companion diagnostics in precision medicine. Nuclear imaging with PET or SPECT and optical imaging technologies are used for in vivo molecular imaging. Nuclear imaging is superior for quantitative imaging, and whole-body analysis is possible even for humans. Optical imaging is superior due to its ease of use, and highly targeted specific imaging is possible with activatable agents. However, with optical imaging using fluorescence, it is difficult to obtain a signal from deep tissue and quantitation is difficult due to the attenuation and scattering of the fluorescent signal. Recently, to overcome these issues, optoacoustic imaging has been used in in vivo imaging. In this article, we review in vivo molecular imaging with nuclear and optical imaging and discuss their utility for precision medicine.
Introduction
Seeing is believing and visualization is the most potent method to convince people of one's opinion. From basic science to clinical study, imaging is widely used in various situations. In the basic sciences, microscopic imaging is necessary to analyze the molecular biology of cells. Recently, one of the technologies of ultra-high-resolution microscopy was awarded the Nobel Prize.
In the clinical setting, several medical imaging technologies, such as CT, MRI, US and PET/SPECT are routinely used to analyze the human body. Since each imaging technology has advantages and disadvantages, the appropriate modality should be chosen in each situation (Table 1) 
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Mikako OGAWA* , ** † and Hideo TAKAKURA* functional and molecular abnormalities. For example, expression of a specific cancer antigen would be investigated by PET or SPECT. Optical imaging also offers functional information with easier operation than PET/SPECT, although the signal can be detected from limited depth due to absorption and scattering of light. Thus, nuclear and optical imaging are appropriate tools for in vivo molecular imaging.
In 2015, in his State of the Union address, former US President Barack Obama announced that he would launch the Precision Medicine Initiative. Precision medicine is an approach used to predict which patients will respond to which therapy to increase therapeutic effectiveness and decrease side-effects by investigating their genomic background. In addition to genome information, expression of disease-related proteins can provide useful information for selecting the appropriate therapeutics for individual patients. For precision medicine, molecular imaging plays an important role as companion diagnostics. For example, immune checkpoint inhibitors, such as antiPD-1 antibody have recently been launched for cancer therapy. For this type of therapy to be effective, it is important to know whether the cancer cells express the target antigen of the drug. 1 Pathological analysis of excised specimens is one way to check for antigen expression. However, since cancer tissue is heterogenous, the antigen-positive portions of the tissue may not be sampled. In vivo molecular imaging can overcome this issue. Whole tissue or even whole-body analysis is possible to evaluate the expression of the therapeutic target.
Monitoring the therapeutic effectiveness is also important during treatment so that treatment can be stopped or changed when a therapeutic effect is not found. Blood tests are the most widely applied method to check for therapeutic effects. However, a blood test is an indirect method to monitor the lesion and it is difficult to detect molecular changes in a specific region. Morphological imaging with CT, MRI and US are also often used to monitor the therapeutic effectiveness. With these molecular imaging methods, we can visualize changes in the size of the lesion, stenosis, edema, etc. But, for some therapies, morphological changes will be seen only after an extended treatment time. In the case of immune checkpoint inhibitors, an initial increase in the size of the tumor is observed due to immune responses. 2 Molecular imaging should be useful for early prediction of therapeutic effectiveness by directly checking the molecular or functional changes in the lesion. In this review article, we will introduce in vivo molecular imaging, which can be used for clinical analysis as well as basic research in mice, with a focus on nuclear imaging and optical imaging technologies.
In vitro vs. in vivo Imaging
In vivo imaging in living subjects is rather different from in vitro imaging of cultured cells in several ways. In culture dishes, the remaining imaging agent can be easily washed out after the appropriate incubation time, or non-specific binding can be blocked by pretreatment with an appropriate reagent. However, during in vivo imaging, the residual imaging agent in the blood and intracellular space cannot be removed from the body, and since blocking reagents may be toxic for living subjects, it is not easy to reduce non-specific binding in vivo.
In addition, we must pay attention to absorption, distribution, metabolism and excretion (ADME) in in vivo imaging. Usually, imaging agents are administered intravenously; thus absorption from injection sites to the blood does not need to be considered. However, distribution to the target tissue is an important step for imaging agents. The imaging agents used for cultured cells often cannot be used for in vivo imaging due to this distribution step. For example, after intravenous injection, cancer imaging agents need to be delivered to the site of the cancer, and brain imaging agents need to be delivered to the brain. The amount of imaging reagent that reaches the site to be imaged should be sufficient for signal detection with the relevant imaging modality. In addition, a sufficient signal-to-noise ratio is necessary for target-specific imaging. Several drug delivery systems (DDS) can be applied for imaging agents to accomplish specific distribution. 3, 4 Metabolism is another important point to consider with respect to the delivery of the imaging agent to the target tissue, since rapid metabolism in the blood and liver may result in low accumulation at the target site. Several types of esterase enzymes are elevated in the blood, although the liver is the main organ that metabolizes such drugs. In addition, metabolism in the liver is important to protect the body from the toxicity of the drug. Toxic effects may result if the imaging agents remain in circulation and are not metabolized. The sideeffects of imaging agents must be much lower than those of the therapeutic drugs. Since imaging agents are just used for diagnosis and not for therapy, they should not have any "effects". Since PET is a very sensitive method and only femto-to picomoles of imaging agents are needed, toxicity is generally not an issue. The sensitivity of SPECT and fluorescence imaging is lower than that of PET, but much higher than those of MRI or CT. Thus, imaging agents for these modalities are safer than the contrast agents used for MRI and CT. Also, the excretion step is important to reduce the toxicity of imaging agents especially for hydrophilic compounds. Hydrophilic compounds are sometimes not metabolized in the liver and are excreted via the kidney, 5 and accumulation of the compounds can be toxic to the kidneys. Thus, the pharmacokinetics of the compounds are of critical importance for in vivo, but not in vitro analysis.
Nuclear Imaging Technologies
For quantitative analysis, nuclear imaging is superior to optical imaging. Molecular imaging agents are composed of a targeting molecule and a signal molecule. Targeting molecules are necessary for specific distribution of the in vivo imaging agents. In PET or SPECT imaging, positron emitters or single photon emitters, respectively, are used as signal molecules (Table 2 ). Since penetration of the electromagnetic rays from these radioisotopes is better than that of optical imaging, and sufficient to penetrate the human body, quantitative imaging is possible. Benedict Cassen first introduced a scanner to "see" the distribution of radioiodine within the human thyroid gland in 1951. 6 After that the basics of tomographic imaging such as PET and SPECT were developed and became popular in the 1980s. Thus, nuclear imaging has developed through human application. In contrast to optical imaging, the application of nuclear imaging in preclinical imaging began much later than for clinical imaging. Quantitativity is the advantage of nuclear imaging; however, high-resolution imaging is not very easy. PET scanners for small animals were developed by several laboratories around the late 1990s and were followed by animal SPECT scanners around 2000. 7, 8 To date, several animal scanners are commercially available, and some are combined with CT or MRI to obtain morphological information. Now, both clinical and preclinical imaging are used for biomedical analysis, such as drug discovery and development, by taking advantage of quantitativity.
Biomedical Analysis by Nuclear Imaging
Many molecular imaging agents for nuclear imaging have been developed. Another advantage of nuclear imaging besides its quantitativity is that small-molecular weight imaging agents are applicable. Positron emitters for PET, such as 11 C, 18 F, and single photon emitters for SPECT, such as 123 I can be incorporated into the small targeting molecules. Small molecules can penetrate the blood-brain barrier, and therefore brain imaging is possible with PET and SPECT. [ 11 C]3-amino- 18 F]FDG-PET in both groups before treatment. After a six-month period of treatment, the aorta was imaged in the control rabbit; however, the aorta of the probucol-treated rabbit was not visualized. 4 -(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([ 11 C] DASB) was used for monitoring selective serotonin reuptake inhibitors in the brain, 9 and the brain dopamine D2 receptor occupancy was investigated in Parkinson's disease patients 10 and schizophrenia patients. 11 We previously developed a nicotinic acetylcholine receptor imaging agent, [12] [13] [14] and quantitatively analyzed the receptor density in Alzheimer's disease patients. 15 Preclinical imaging is also utilized to estimate the therapeutic dose during drug development 16 and to evaluate receptor functions in the brain. 17 For example, dose dependent dopamine released in the brain after the drug administration can be measured by [ 11 C]raclopride PET imaging in rats, and it provides the important information for drug development. 16 20 Using this method, the therapeutic effect was successfully analyzed by PET before changes in blood cholesterol level were detected (Fig. 1) . 21 Now, this noninvasive quantitative method is applied for clinical studies. 22 (Fig. 2) . 25, 26 Antibodies are useful targeting molecules to analyze the expression of specific antigens in cancer in combination with radioisotopes. Since the molecular weight of antibodies is large, large signal molecules can be used for antibody labeling. Thus, metal radionuclides with appropriate chelates can be used for radiolabeling. When using an antibody as a targeting molecule, it is important to pay attention to the pharmacokinetics of the antibody in vivo. The half-lives of intact antibodies are 7 -14 days. 27 With short half-life radionuclides, only blood pool images should be obtained and antigen-specific imaging is impossible.
111 In (half-life: 67.3 h) is an appropriate radiotracer for antibody labeling, and is used for both clinical and preclinical imaging by SPECT. 28,29 111 In-labeled antibodies are useful for monitoring targeted therapy. 3, 31 For PET imaging, 89 Zr (halflife: 78.4 h) can be used for imaging with intact antibodies. 32, 33 Antibody fragments are used for specific imaging over short time periods since the blood half-lives are shorter for the fragments. 34 Shorter half-life radionuclides are used for this purpose, such as 64 Cu (half-life: 12.7 h) for PET 35, 36 and 99m Tc (half-life: 6.02 h) for SPECT. 37, 38 Recently, antibody imaging has been applied for prediction of the therapeutic effect of immune checkpoint inhibitors. [39] [40] [41] Clinical trials with 89 Zr labeled anti-PD-1 antibody started in the USA in 2017 (NCT02760225). Evaluation of the therapeutic response of immune checkpoint inhibitors is also tested with [
18 F]FDG. 42, 43 However, since [ 18 F]FDG accumulates in the immune activated region, it may not be easy to predict the therapeutic effect in some patients. 44 In some cases, a combination of several imaging agents might be effective for prediction and monitoring the therapies.
Optical Imaging Technologies
Optical imaging is a powerful and widespread method for visualizing biomolecules in the research field due to good spatiotemporal resolution, easy-to-use operability, lower cost for agents and detectors, and real-time measurement. Molecular imaging agents can be developed by the same method as PET/ SPECT agents, meaning that they consist of a target moiety and a fluorescent moiety (Fig. 3) . This type of agent is called an "active agent". Such agents always emit fluorescence and are accumulated or retained in cells with affinity to the specific molecules; therefore, it takes time until they bind to target molecules and the unbound agents are removed to generate a high signal-to-background ratio. Another type of optical imaging agent is an "activity-based agent" or "activatable agent" whose signal intensity changes when it encounters or reacts with target molecules, generating a high signal-to-background ratio in a shorter time (Fig. 3) . This characteristic is unique to fluorescence agents and many researchers have been interested in the development of various molecular designs. Thanks to their efforts, more flexible design strategies, such as Förster resonance energy transfer, 45, 46 photoinduced electron transfer, 45, 47 spirocyclization 48 and charge transfer, 49 than those for other modalities have been developed and applied to various target molecules. However, the molecular size of both types of optical imaging agents is larger than those used for PET/SPECT, so the agents often suffer from lower affinity, cell membrane permeability and catalytic constants. Another advantage of fluorescence is that several emission spectra can be detected by using appropriate filters, so that we can visualize multiple target molecules at one time. To take advantage of these options, researchers are customizing imaging agents to detect the biomolecules of interest.
Optical imaging began with microscopy for single cell analysis, and then developed into more complicated systems like those for living animals and humans. In the application of optical imaging for in vivo use, the wavelength of fluorescent agents must be considered, because many components of living subjects absorb fluorescence. Near infrared (NIR) wavelengths (650 -900 nm) are thought to be suitable for in vivo imaging due to relatively low absorption by hemoglobin and water. 45 Also, background fluorescence from endogenous biomolecules is lower in the NIR region. Although shorter wavelengths would be applicable at and near the surface, NIR wavelengths are usually preferred. Cyanine dyes, in particular Cy5.5, Cy7 and ICG, are major NIR fluorophores for in vivo imaging. To date, many optical imaging studies utilizing various agents have been conducted and much evidence for the usefulness of optical imaging has accumulated. Some have utilized target molecules that are associated with specific diseases and tumors, and were applied in clinical trials for diagnostic agents, contrast agents and surgery guidance. However, the penetration capability of fluorescence through the human body is quite poor compared to PET/SPECT modality. Therefore, optical imaging in clinical use is limited. However, optical imaging can improve the medical manipulation and prognosis of patients. These challenges should be the focus of future research to further the development and utility of optical imaging. In other mechanisms, such as photoinduced electron transfer, a quencher also works as a reaction moiety for target molecules. Upon reaction with the target molecules, the chemical structure of the quencher changes and it loses quenching capacity, leading to recovery of the signal.
Biomedical Analysis by Optical Imaging
One of the most advantageous applications of optical imaging in clinical use is image-guided surgery to remove tumor tissue. Surgeons want to remove all tumor tissue while preserving as much normal tissue as possible, because residual cancer cells can lead to recurrence and re-surgery, but on the other hand, removal of too much normal tissue can result in a poor prognosis for the patient. However, the boundary between tumor lesions and normal tissue cannot be distinguished by the eye or from morphological information. In this case, intraoperative optical imaging providing functional information is suitable to determine the boundary compared to PET/SPECT modalities due to its good spatial resolution and real-time observation. Currently, the clinically approved agents for optical imaging are indocyanine green (ICG) and fluorescein (Table 3) . While fluorescein emits green fluorescence, which should be well absorbed by hemoglobin, ICG exhibits NIR light with a peak over 800 nm and the signal can be detected from deeper human tissue. Indeed, ICG has been used as an intraoperative imaging agent in some kinds of cancer, such as liver cancer. 50 However, the mechanism of its accumulation in tumor tissue is not yet fully understood, although it depends on the type of cancer cells. This is the main limitation of image-guided surgery with ICG.
Optical imaging with active agents targeted to specific molecules should be more applicable, because specific biomarkers for malignant cancers have been screened and some candidates have been found. [51] [52] [53] [54] Unfortunately, to our knowledge, the optical imaging agents for such molecules have not yet been clinically approved. The most promising target is folate receptor-α (FR-α), which is overexpressed on the surface of many cancer cells. In 2011, the first in-human trial of the agent for FR-α was carried out in image-guided surgery of ovarian cancer, 55 and the NIR active agent 56 is in a Phase III clinical trial (NCT03180307). Other promising candidates for target biomolecules for cancer imaging include the prostatespecific membrane antigen (PSMA), 57, 58 cycloxygenase-2 (COX-2) 59, 60 and chlorotoxin venom (CTX). 61, 62 A preclinical study 63 and Phase I clinical trial of the NIR optical imaging agent for CTX have been completed, and its safety and promising results were demonstrated (NCT02496065).
Activatable optical imaging agents for image-guided surgery have been also reported. The target molecules for cancer imaging are generally enzymes, such as cathepsins, 64 ,65 matrix metalloproteinases, 66, 67 γ-glutamyltranspeptidase (GGT) 68 and glycosidases. 69 To take advantage of the quick response of activatable agents, topical administration with a spray just before, during and after surgery (i.e. ex vivo) can be applied. 70 Such optical imaging agents have not yet been clinically approved, but promising results in preclinical studies have been extensively reported. 71 These technologies will help surgeons and medical doctors to offer better medical care for patients.
New technologies to visualize specific tissues in the human body have emerged. The technology with the most potential is optoacoustic imaging in which the contrast agents are excited by irradiation with light and the signal is detected as ultrasound caused by thermoelastic expansion. 72 Optoacoustic imaging has advantages of both optical and ultrasound modalities. That is, optoacoustic signals can provide functional information like fluorescence and be detected from much deeper tissue (up to several centimeters). Therefore, optoacoustic imaging can overcome the drawback of the weak penetration capability of optical imaging. Currently, two optoacoustic imaging systems are commercially available (MSOT from iThera Medical and Nexus 128 from Endra Life Sciences) and much of the research using both active and activatable optoacoustic imaging agents has been conducted with an aim toward clinical use for the human body. 73, 74 Other agents for optical imaging are based on nanoparticles or nanomaterials consisting of polymers and inorganic materials. Optical imaging with these agents has advantages compared to those consisting of small molecules, such as high signal-tobackground ratio, high photostability and high biostability in living subjects. 75 Nevertheless, they have not been applied in clinical use because of low production reproducibility and insufficient information regarding their interaction and biodistribution in vivo.
Approaches for Theranostics
"Theranostics" is an approach combining "Therapy" and "Diagnosis". Theranostics provides an additional component to precision medicine. Biomedical imaging is a powerful tool to accomplish the appropriate therapy for each patient as described above. However, radionuclides can be used not only for imaging but also for therapy. The combination of radio-imaging and radio-therapy is called "radio-theranostics". Usually, the same targeting molecules, such as antibodies (including antibody fragments), peptides and nano-particles, are used for both imaging and therapy. The combination of 111 In (diagnosis with SPECT) or 68 Ga (half-life: 68 min, diagnosis with PET) with 177 Lu or 90 Y (therapy) is commonly used for this purpose since the same or similar chelates can be used for these radionuclides. [76] [77] [78] [79] That is, only the radionuclides differ between diagnosis and therapy. The patient is quantitatively analyzed by SPECT or PET to investigate whether the antigens or receptors are positive or not, then the selected patient will be treated by therapeutic radionuclides.
Theranostics using light is also applied for clinic use. After administration of 5-amino levulinic acid (5-ALA) in the human body, fluorescent Protoporphyrin IX, a heme intermediate metabolite, is selectively accumulated in certain cancer cells, such as gliomas and bladder cancer. 80 Protoporphyrin IX is a photosensitizer that produces toxic single oxygen upon laser irradiation, leading to application of diagnosis for cancer and photodynamic therapy (PDT). Photoimmunotherapy (PIT), which is currently under a Phase II clinical trial, is another type of theranostics. In PIT, an antibody conjugated with IR-700, an NIR phothalocyanine dye, is used as an active agent and can be excited by laser irradiation followed by visualization of the tumor tissue and induction of immunogenic cell death. 81, 82 
Conclusions
Biomedical imaging is a powerful tool both in pre-clinical and clinical studies.
However, each imaging modality has disadvantages and advantages. Therefore, multimodal imaging should have potential to compensate for the disadvantages and enhance the advantages of each modality. We previously reported multimodal imaging using an antibody labeled with activatable fluorescence and a radionuclide. 83 Nuclear imaging is superior to optical imaging for quantitative imaging but inferior for specific imaging due to the always-ON feature. We characterized molecular targets with activatable agents for optical imaging, and visualized and quantified the delivery of targeted antibodies using radioactive labeling (Fig. 4) . Simultaneous visualization, characterization, and measurement of biological processes should be possible with multimodal imaging.
Furthermore, the combination of multimodal imaging with therapy would be most valuable for precision medicine in each patient. 
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